These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 27570425)

  • 41. Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD).
    Kim MS; Kung S; Grewal T; Roufogalis BD
    Curr Pharm Biotechnol; 2012 Feb; 13(2):278-91. PubMed ID: 21470125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines.
    Zhu JZ; Yi HW; Huang W; Pang T; Zhou HP; Wu XD
    Chin J Nat Med; 2020 Mar; 18(3):161-168. PubMed ID: 32245585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence-Based Phytotherapy in Europe: Where Do We Stand?
    Fürst R; Zündorf I
    Planta Med; 2015 Aug; 81(12-13):962-7. PubMed ID: 25922913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Omics and its potential impact on R&D and regulation of complex herbal products.
    Pelkonen O; Pasanen M; Lindon JC; Chan K; Zhao L; Deal G; Xu Q; Fan TP
    J Ethnopharmacol; 2012 Apr; 140(3):587-93. PubMed ID: 22313626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
    Yang Y; Zhao Y; Li W; Wu Y; Wang X; Wang Y; Liu T; Ye T; Xie Y; Cheng Z; He J; Bai P; Zhang Y; Ouyang L
    Eur J Med Chem; 2020 Jul; 197():112311. PubMed ID: 32339855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review.
    Yatoo MI; Gopalakrishnan A; Saxena A; Parray OR; Tufani NA; Chakraborty S; Tiwari R; Dhama K; Iqbal HMN
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(1):39-58. PubMed ID: 29336271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Analysis on mechanisms and medication rules of herbal prescriptions for nonalcoholic fatty liver disease based on methods of data mining and biological information].
    Ding J; Zhang B; Wang PJ; He GN; Wei DM; Ding JL; Wang BC
    Zhongguo Zhong Yao Za Zhi; 2019 Apr; 44(8):1689-1695. PubMed ID: 31090336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-alcoholic fatty liver disease and flavonoids: Current perspectives.
    Shin JH; Jung JH
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):17-24. PubMed ID: 27545758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contemporary overview on clinical trials and future prospects of hepato-protective herbal medicines.
    Alvari A; Mehrnaz SO; Ahmad FJ; Abdin MZ
    Rev Recent Clin Trials; 2012 Aug; 7(3):214-23. PubMed ID: 22540904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic investigation of the mechanism of Cichorium glandulosum on type 2 diabetes mellitus accompanied with non-alcoholic fatty liver rats.
    Qin H; Chen H; Zou Y; Zhang X; Wei C; Chen W; Xie Z; Yao M; Han B
    Food Funct; 2019 May; 10(5):2450-2460. PubMed ID: 30969285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phytotherapeutic potential of natural herbal medicines for the treatment of mild-to-severe atopic dermatitis: A review of human clinical studies.
    Hussain Z; Thu HE; Shuid AN; Kesharwani P; Khan S; Hussain F
    Biomed Pharmacother; 2017 Sep; 93():596-608. PubMed ID: 28686974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of xuezhlkang capsule in intervening different Chinese medical syndrome patterns of non-alcoholic fatty liver disease complicated with carotid atherosclerosis].
    Ou MY; Xu SH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Feb; 31(2):159-63. PubMed ID: 21425565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ophiopogon japonicus--A phytochemical, ethnomedicinal and pharmacological review.
    Chen MH; Chen XJ; Wang M; Lin LG; Wang YT
    J Ethnopharmacol; 2016 Apr; 181():193-213. PubMed ID: 26826325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Japanese herbal medicines shosaikoto, inchinkoto, and juzentaihoto inhibit high-fat diet-induced nonalcoholic steatohepatitis in db/db mice.
    Takahashi Y; Soejima Y; Kumagai A; Watanabe M; Uozaki H; Fukusato T
    Pathol Int; 2014 Oct; 64(10):490-8. PubMed ID: 25229199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
    Im AR; Kim YH; Lee HW; Song KH
    J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus.
    Li WL; Zheng HC; Bukuru J; De Kimpe N
    J Ethnopharmacol; 2004 May; 92(1):1-21. PubMed ID: 15099842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidiabetic herbal drugs officially approved in China.
    Jia W; Gao W; Tang L
    Phytother Res; 2003 Dec; 17(10):1127-34. PubMed ID: 14669243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research Advances on Hepatotoxicity of Herbal Medicines in China.
    Liu C; Fan H; Li Y; Xiao X
    Biomed Res Int; 2016; 2016():7150391. PubMed ID: 28078299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Herbal Extracts and Natural Products in Alleviating Non-alcoholic Fatty Liver Disease via Activating Autophagy.
    Zhang L; Yao Z; Ji G
    Front Pharmacol; 2018; 9():1459. PubMed ID: 30618753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.